VEGFA and arthritic joint disease: These mediators promote inflammation, cartilage degradation, and neovascularization via activation of angiogenetic factors like vascular endothelial growth factor (VEGF),4,5 reportedly secreted from mechanically overloaded chondrocytes6 and in OA joints in vivo.7 VEGF also affects chondrocytic metabolism, leading to release of matrix metalloproteinases that degrade cartilage matrix.8 Anti-VEGF polyclonal antibody markedly attenuated disease severity in arthritis,9 indicating anti-angiogenesis as novel OA treatment.